Clinical Report: 4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD
Overview
4D Molecular Therapeutics has completed enrollment for the 4FRONT-1 phase 3 trial, evaluating the gene therapy 4D-150 in wet age-related macular degeneration (AMD). This study aims to assess the noninferiority of 4D-150, administered as a single intravitreal injection, compared to aflibercept 2 mg, administered every 8 weeks, in improving visual acuity and reducing treatment burden.
Background
Wet age-related macular degeneration is a leading cause of vision loss in older adults, necessitating effective treatment options. Current standard care involves frequent intravitreal injections of anti-VEGF agents, which can be burdensome for patients. Gene therapy presents a potential one-time treatment solution, aiming to provide sustained therapeutic effects through the delivery of genes encoding aflibercept and an anti-VEGF-C component, thereby reducing the need for ongoing injections.
Data Highlights
No numerical data available at this time.
Key Findings
The 4FRONT-1 trial is a multicenter, randomized, double-masked study. Enrollment included treatment-naïve patients at over 100 sites across North America. The primary endpoint is noninferiority in mean change from baseline in best-corrected visual acuity at 52 weeks. A key secondary endpoint focuses on the reduction in treatment burden compared to aflibercept. Top-line data from the trial are expected in the first half of 2027. The trial is part of a broader registrational program that includes a second phase 3 study, 4FRONT-2, which is enrolling both treatment-naïve and recently diagnosed treatment-experienced patients globally, with enrollment expected to conclude in the second half of 2026.Clinical Implications
The completion of enrollment in the 4FRONT-1 trial marks a significant step toward evaluating gene therapy as a viable treatment for wet AMD. If successful, 4D-150 could reduce the treatment burden associated with current anti-VEGF therapies, improving patient adherence and outcomes. However, challenges such as long-term safety and efficacy data will be crucial for clinical adoption.
Conclusion
The 4FRONT-1 trial's findings may pave the way for innovative treatment strategies in wet AMD, potentially transforming the management of this condition. Continued monitoring of trial outcomes will be essential for understanding the long-term implications of gene therapy in clinical practice.
Related Resources & Content
- Ophthalmology Management, 2026 -- 4DMT Completes Enrollment in Wet AMD Phase 3 Trial
- Retinal Physician, 2025 -- 4DMT SPECTRA trial interim results
- Ophthalmology Management, 2025 -- 4DMT Presents Positive 60 Week Results from 4D150 SPECTRA Clinical Trial in DME
- Nature Index, 2025 -- Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial
- retinal physician — Video: Dual-Action Gene Therapy for DME Shows Safety and Durability
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial | Articles | Nature Index
- 4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD) | 4D Molecular Therapeutics
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
